Synapse - Works

Results (13087)

Results of T cell depleted (TCD) myeloablative hematopoietic stem cell transplants (HSCT) in patients with hematologic malignancies >= 55 yrs of age

Meeting Abstract

Jakubowski, A. A.; Papadopoulos, E. B.; Castro-Malaspina, H. R.; Hsu, K.; Perales, M. A.; Van Den Brink, M.; Young, J. W.; O'Reilly, R. J.
Blood (2005)

Fulltext@MSK | Save

Modification of delayed radiation nephropathy following internal irradiation with alpha particles

Meeting Abstract

Jaggi, J. S.; Seshan, S. V.; McDevitt, M. R.; Scheinberg, D. A.
Nephrology (2005)

Fulltext@MSK | Save

Fludarabine pharmacokinetics in nonmyeloablative hematopoietic cell transplantation (HCT): Association with engraftment and neurotoxicty

Meeting Abstract

Jacobson, P. A.; Rogosheske, J.; Green, K.; Brunstein, C.; Barker, J.; Miller, J.; Wagner, J.; McGlave, P.; Tan, Y.; Weisdoff, D.
Blood (2005)

Fulltext@MSK | Save

Oral bioavailability of mycophenolate mofetil in patients undergoing nonmyeloablative hematopoietic cell transplantation (HCT) is poor and highly variable

Meeting Abstract

Jacobson, P.; Kathleen, G.; Rogosheske, J.; Brunstein, C.; Barker, J.; Defor, T.; McGlave, P.; Weisdorf, D.
Blood (2005)

Fulltext@MSK | Save

Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-Cell lymphomas: Minimal benefit when analyzed by intent to treat

Meeting Abstract

Horwitz, S.; Moskowitz, C.; Kewalramani, T.; Hamlin, P.; Straus, D.; O'connor, O.; Noy, A.; Portlock, C.; Nimer, S.; Palomba, M. L.; more...
Blood (2005)

Fulltext@MSK | Save

Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs

Meeting Abstract

Heaney, M. L.; Gardner, J. R.; Karasavvas, N.; Golde, D. W.; Scheinberg, D. A.; Smith, E. A.; O'Connor, O. A.
Blood (2005)

Fulltext@MSK | Save

The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for multiple myeloma

Meeting Abstract

Hassoun, H.; Reich, L.; Klimek, V. M.; Dhodapkar, M.; Cohen, A.; Kewalramani, T.; Riedel, E. R.; Hedvat, C. V.; Teruya-Feldstein, J.; Filippa, D. A.; more...
Blood (2005)

Fulltext@MSK | Save

Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin((R))) for elderly high risk patients with untreated DLBCL

Meeting Abstract

Hamlin, P. A.; Moskowitz, C. H.; Wegner, B. C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Dumitrescu, O.; Palomba, M. L.; Horwitz, S. M.; O'Connor, O. A.; more...
Blood (2005)

Fulltext@MSK | Save

Induction with combined modality therapy followed by immunomodulated post remission therapy for newly diagnosed acute myeloid leukemia (AML)

Meeting Abstract

Gupta, S.; Weiss, M. A.; Jurcic, J. G.; Chanel, S.; Wilson, B. A.; Biederman, E.; Berman, E.; Scheinberg, D. A.; Maslak, P. G.
Blood (2005)

Fulltext@MSK | Save

Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL)

Meeting Abstract

Gregory, S. A.; Leonard, J. P.; Vose, J. M.; Zelenetz, A. D.; Horning, S. J.; Knox, S. J.; Lister, T. A.; Radford, J. A.; Press, O. W.; Kaminski, M. S.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save